Irinotecan/cisplatin versus etoposide/cisplatin for patients with extensive stage small cell lung cancer: A systematic review

Chinese Journal of Lung Cancer

Volumn 12, Issue 8, 2009, Pages 884-888

  Yao, Nan ^a   Jiang, Lei ^a   Yang, Kehu ^a   Ye, Yancheng ^b   Mi, Denghai ^a,c   Min, Guangtao ^a  

^a LANZHOU UNIVERSITY   (China)

^b Wuwei Tumor Hospital of Gansu Province   (China)

^c Gansu Province People Hospital   (China)

Author keywords

Cisplatin; Etoposide; Irinotecan; Lung neoplasms; Systematic review

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DATA BASE; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; LUNG SMALL CELL CANCER; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; SCIENTIFIC LITERATURE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 69949128230     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.08.10     Document Type: Article

References (12)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology, 2007, 18(3): 581-592.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
3. Bai CX, Zhang X. status quo for lung cancer treatment. Chin J Tubercul Resp, 2006, 29(3): 146.
4. Levi F, Franceschi S, La Vecchia C, et al. Lung carcinoma trends by histologic type in Vaud and Neuchatel, Switzerland, 1974-1994. Cancer, 1997, 79(5): 906-914.
5. Scottish Intercollegiate Guidelines Network (SIGN). Management of patients with lung cancer. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2005 Feb. 63 p. (SIGN publication; no. 80).
6. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006, 24(28): 4539-4544. (Pubitemid 46630948)
7. Merck Manual Professional Edition, Online Edition. Lung carcinoma [EB/OL]. (2008-3) [2009-02-23].
8. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002, 346(2): 85-91. (Pubitemid 34438898)
9. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol, 2006, 24(13): 2038-2043. (Pubitemid 46622112)
10. Lara PN Jr, Natale R, Crowley J, et al. Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124. J Clin Oncol, 2009, 27(15): 2530-2535.
11. Pan D, Hou M, Li H, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for small cell lung cancer: a randomized clinical trial. Chin J Lung Cancer, 2006, 9(5): 443-446. (Pubitemid 44646018)
12. Simon GR, Turrisi A; American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132(3 Suppl): 324S-339S.